FDA Accepts Supplemental Application for POMALYST by Bristol
The FDA has accepted a supplemental application for POMALYST (pomalidomide) submitted by Bristol.
Asset / Drug
Drug and asset intelligence for POMALYST with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Immunomodulator
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.